更新于：2024-05-01
Rupatadine Fumarate
富马酸卢帕他定
更新于：2024-05-01
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C26H26ClN3 |
InChIKeyWUZYKBABMWJHDL-UHFFFAOYSA-N |
CAS号158876-82-5 |
查看全部结构式(2)
关联
59
项与 富马酸卢帕他定 相关的临床试验富马酸卢帕他定片在健康成年受试者中进行的单中心、随机、开放、单次给药、两序列、四周期、完全重复交叉、空腹和餐后生物等效性试验
富马酸卢帕他定片在健康受试者中的单中心、单剂量、2制剂、2周期、2序列、开放、随机、交叉的平均生物等效性试验
富马酸卢帕他定片在健康成年受试者中进行的单中心、随机、开放、单次给药、两序列、四周期、完全重复交叉、空腹和餐后生物等效性试验
100 项与 富马酸卢帕他定 相关的临床结果
登录后查看更多信息
100 项与 富马酸卢帕他定 相关的转化医学
登录后查看更多信息
100 项与 富马酸卢帕他定 相关的专利（医药）
登录后查看更多信息
170
项与 富马酸卢帕他定 相关的文献（医药）2024-01-30BMC chemistry
Environmentally benign liquid chromatographic method for concurrent estimation of four antihistaminic drugs applying factorial design approach.
Article
作者: Rana Ghonim ; Manar M Tolba ; Fawzia Ibrahim ; Mohamed I El-Awady
In the last few decades, green analytical chemistry (GAC) has become a smart magical solution for the qualification and quantification of many drugs. In the current study, a direct, sensitive, and green RP-HPLC method was used to separate three anti-histaminic combinations rupatadine/montelukast, desloratadine/montelukast, fexofenadine/montelukast, and finally a mixture of rupatadine and its metabolite; desloratadine in less than 20 min. The developed method was optimized by a 23 full factorial design to improve the chromatographic responses. The proposed method was used to analyze these antihistaminic combinations at different pharmaceutical ratios. The linearity range is from 1 to 10 µg/mL for rupatadine, desloratadine, and montelukast, while for fexofenadine from 1 to 24 µg/mL drugs. The proposed method is useful in common quality control analysis of the investigated quaternary combinations because of its non-toxic and eco-friendly effects on the environment and human beings. The proposed procedure was thoroughly validated in accordance with ICH guidelines and was revealed to be accurate, reproducible, and selective. The developed methods were compared with a reported reference comparison method, where no significant difference was observed.
2024-01-30Angewandte Chemie (International ed. in English)
Eu(OTf)3-Catalyzed Formal Dipolar [4π + 2σ] Cycloaddition of Bicyclo-[1.1.0]butanes with Nitrones: Access to Polysubstituted 2-Oxa-3-azabicyclo[3.1.1]heptanes.
Article
作者: Jian Zhang ; Jia-Yi Su ; Hanliang Zheng ; Hao Li ; Wei-Ping Deng
Herein, we have synthesized multifunctionalized 2-oxa-3-azabicyclo[3.1.1]heptanes, which are considered potential bioisosteres for meta-substituted arenes, through Eu(OTf)3-catalyzed formal dipolar [4π+2σ] cycloaddition of bicyclo[1.1.0]butanes with nitrones. This methodology represents the initial instance of fabricating bicyclo[3.1.1]heptanes adorned with multiple heteroatoms. The protocol exhibits both mild reaction conditions and a good tolerance for various functional groups. Computational density functional theory calculations support that the reaction mechanism likely involves a nucleophilic addition of nitrones to bicyclo[1.1.0]butanes, succeeded by an intramolecular cyclization. The synthetic utility of this novel protocol has been demonstrated in the concise synthesis of the analogue of Rupatadine.
2024-01-01Drugs in context
How to handle off-label prescriptions of rupatadine, a second-generation antihistamine and PAF antagonist: a review.
Review
作者: Iñaki Izquierdo ; Laia Casas ; Susana Cabrera ; Alberto Fernandez
The off-label use of second-generation antihistamines, used outside of the formal indications authorized by regulatory authorities, in different age groups, doses or in special populations, is very common for many allergic, autoimmune and dermatological diseases. The off-label use of rupatadine (a second-generation antihistamine with PAF antagonist activity) in these conditions is reviewed here, including in combination with immunotherapy in the treatment of food allergy or allergic rhinitis, at high doses in chronic urticaria, and with prescriptions of less common but challenging conditions such as skin pruritus or mast cell activation disorders like mastocytosis. Rupatadine use is reviewed herein to confirm if its off-label management is supported by well-designed clinical trials or by published real-world cases. This review will contribute to increasing compliance and achieving better results in clinical practice. Off-label use of rupatadine should be left to the discretion of the prescribing healthcare professional after careful clinical evaluation.
100 项与 富马酸卢帕他定 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 皮炎 | 批准上市 | 日本 更多 | |
| 湿疹 | 批准上市 | 日本 更多 | |
| 常年性变应性鼻炎 | 批准上市 | 日本 更多 | |
| 荨麻疹 | 批准上市 | 日本 更多 | |
| 过敏性鼻炎 | 批准上市 | 日本 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 248 | (夢衊齋網簾醖衊齋顧憲) = 4.35% for placebo, 2.86% for 5 mg-, 4.05% for 10 mg- and 4.29% for 20 mg-rupatadine-treated group 鬱憲鹹醖鬱鹹膚鹽遞鏇 (襯夢窪窪廠觸艱鏇製齋 ) 更多 | - | 2007-06-30 | |||
N/A | - | Standard pre-medications (SP) | (鹹壓淵窪鹹遞膚遞顧憲) = 艱築淵襯衊範網築構鹽 網夢鬱襯鹹鑰窪淵淵淵 (淵齋夢淵艱蓋鹽夢選選, [0 ~ 63]) 更多 | 积极 | 2019-06-15 | ||
(鹹壓淵窪鹹遞膚遞顧憲) = 餘廠積簾艱繭膚淵願簾 網夢鬱襯鹹鑰窪淵淵淵 (淵齋夢淵艱蓋鹽夢選選, [0 ~ 63]) 更多 | |||||||
N/A | - | Standard pre-medications (SP) | 觸觸餘淵壓顧遞遞鬱遞(鹹觸餘製餘淵構夢糧範) = 膚築鹽醖鏇繭選獵鏇窪 廠壓築範膚簾網遞膚膚 (築餘鏇網選衊艱願齋艱, [0 ~ 63]) 更多 | 积极 | 2019-05-26 | ||
觸觸餘淵壓顧遞遞鬱遞(鹹觸餘製餘淵構夢糧範) = 餘憲簾繭範艱糧遞糧憲 廠壓築範膚簾網遞膚膚 (築餘鏇網選衊艱願齋艱, [0 ~ 63]) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用